Suppr超能文献

5-羟色胺7、神经发生与抗抑郁药:一条治疗抑郁症的前景广阔的治疗途径

5-HT7, neurogenesis and antidepressants: a promising therapeutic axis for treating depression.

作者信息

Nandam L Sanjay, Jhaveri Dhanisha, Bartlett Perry

机构信息

The Queensland Brain Institute, University of Queensland, St Lucia, Australia.

出版信息

Clin Exp Pharmacol Physiol. 2007 May-Jun;34(5-6):546-51. doi: 10.1111/j.1440-1681.2007.04608.x.

Abstract
  1. There is mounting evidence that a wide range of antidepressants share the common feature of increasing hippocampal neurogenesis. The specificity of this association has suggested that an ability to increase neurogenesis might be a useful paradigm to screen for compounds with antidepressant activity. 2. The hope of developing better antidepressants has stimulated research into the molecular control of neurogenesis and here we summarize some of the recent findings. We also review recent work that highlights 5-HT7 receptor as a promising molecular target in the treatment of depression. 3. In summary, it appears that 5-HT7 antagonism is capable of producing diverse antidepressant-like behavioural effects, alters hippocampal neuronal morphology and synergistically regulates hippocampal neurogenesis.
摘要
  1. 越来越多的证据表明,多种抗抑郁药都具有增加海马神经发生的共同特征。这种关联的特异性表明,增加神经发生的能力可能是筛选具有抗抑郁活性化合物的有用范式。2. 开发更好的抗抑郁药的希望激发了对神经发生分子控制的研究,在此我们总结一些近期的发现。我们还回顾了近期的研究工作,这些工作突出了5-HT7受体作为治疗抑郁症的一个有前景的分子靶点。3. 总之,5-HT7拮抗作用似乎能够产生多种类似抗抑郁的行为效应,改变海马神经元形态,并协同调节海马神经发生。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验